Objective: We evaluated the efficacy and safety of tacrolimus in systemic lupus erythematosus patients with refractory thrombocytopenia. Methods: We retrospectively reviewed the data for 20 systemic lupus erythematosus patients with refractory thrombocytopenia and treated with tacrolimus during the period January 2013 to January 2015. In addition to glucocorticoids, all patients were treated with tacrolimus, 1 mg taken twice daily. The clinical effect of tacrolimus treatment in patients was evaluated by analysis of platelet counts at baseline and after one, three and six months of tacrolimus treatment. Levels of anti-double-stranded DNA antibodies and complement C3, C4 were determined individually. Results: After one month of tacrolimus treatment, three patients (15%) did not respond, three patients (15%) achieved a complete response and the other 14 patients (75%) achieved a partial response. After three months of tacrolimus treatment, the platelet counts of all patients were significantly improved. A partial response was seen in 14 patients (75%) and the complete response rate increased to 25% (five patients). After six months, all patients attained partial response or complete response without relapse, and the rate of complete response increased to 75%. Compared to pretreatment, anti-double-stranded DNA antibody levels and the disease activity index score were markedly decreased after tacrolimus treatment. The levels of serum C3 and C4 were increased significantly (P < 0.05). Conclusions: Our survey revealed that a six-month course of tacrolimus is a safe and effective treatment for systemic lupus erythematosus patients with refractory thrombocytopenia. Lupus (2018) 27, 60-65.
Introduction
Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease characterized by the production of a large number of autoantibodies in the blood. There is multi-organ involvement; skin, bone marrow, kidneys, joints, heart, brain and other organs can be affected. 1 Thrombocytopenia is a common clinical manifestation of SLE. Previous studies reported that between 7% and 30% of patients with SLE may be affected by thrombocytopenia. [2] [3] [4] Patients with mild and moderate thrombocytopenia can present with signs of bleeding from superficial areas of the body. Severe thrombocytopenia can lead to hemorrhage of internal organs and is potentially life threatening. Therefore, effective treatments for thrombocytopenia associated with SLE are important clinically.
Numerous immune-modulating medications have been used to treat thrombocytopenia of SLE. Glucocorticoids (GCs) are administered first. However, in some patients, thrombocytopenia does not respond to GC monotherapy or recurs despite GC therapy. 5 Other medications, including danazol, intravenous immunoglobulin, azathioprine, cyclosporine (CSA), 6 and vincristine (VCR), 7 can be added to the GC. Some patients eventually require splenectomy. 8 Despite the reported success of such measures in correcting thrombocytopenia, a subset of patients still remain refractory or develop significant clinical side effects. Therefore, effective and less toxic new treatment strategies are needed.
Tacrolimus, also known as FK506, was isolated from Streptomyces tsukubaensis, a soil fungus found in Northern Japan. As a relatively new calcineurin inhibitor, tacrolimus has been reported to be a useful alternative immunosuppressive agent. Numerous clinical trials conducted over the past decade have demonstrated tacrolimus to be a cornerstone immunosuppressant in renal transplants. Compared with cyclosporin treatment, tacrolimus has been shown to be associated with decreased acute and chronic rejection, and improved renal function over the long term posttransplant. The drug has also been shown to be effective in liver, heart and lung transplantation. 9, 10 In recent years, tacrolimus has been widely used in the treatment of SLE.
11 A double-blind, placebocontrolled study in 63 patients showed that the addition of tacrolimus at 3 mg/day to GC therapy for 28 weeks resulted in significant improvement in lupus nephritis compared with placebo. 12 In addition, Duddridge and Powell were the first to report the efficacy of tacrolimus in the treatment of two SLE patients with severe cutaneous vasculitis, where cyclophosphamide and CSA had failed. 13 A retrospective study found that the addition of tacrolimus therapy, without increasing the GC dose, was effective and safe for minor flares in patients with SLE. 14 There are no data on the efficacy and safety of tacrolimus in patients with SLE and refractory thrombocytopenia. We investigated these aspects using a retrospective cohort design.
Materials and methods

Patients
We retrospectively examined data on 20 SLE patients with refractory thrombocytopenia who were treated with tacrolimus during the period of January 2013 to January 2015 in the ward at the Department of Rheumatology, The First Affiliated Hospital of Liaoning Medical University. Approval was obtained from an independent ethics committee.
The inclusion criteria for this study were as follows: patients had to have previously fulfilled the revised American College of Rheumatology (ACR) criteria for SLE. Severe thrombocytopenia was defined as a platelet count less than 10 Â 10 9 /L or <30 Â 10 9 /L with bleeding propensity. All patients had failed at least one course of methylprednisolone pulse therapy (1 g/day for three consecutive days). Before tacrolimus treatment, all patients had received at least one kind of immunosuppressive medication in addition to corticosteroids, including CSA (3-5 mg/kg/day), danazol (300-400 mg/day orally), VCR (1-2 mg, weekly) and interleukin-11 (IL-11, 25-50 mg/kg/day injection).
Five patients had received intravenous immunoglobin (IVIG, 20 g/day for three to five consecutive days). All patients failed to respond sufficiently to their prior therapy. Additionally, all patients had agreed to use tacrolimus for six months and completed follow-up examinations.
Treatment protocol
All patients were treated with tacrolimus at a dose of 1 mg taken twice daily. All patients were advised to take tacrolimus at least one hour before a meal or two hours after a meal. While the patient was receiving tacrolimus, blood samples (1 mL) were collected during every clinic visit for the determination of whole blood tacrolimus levels. Dose adjustment was done with the target level of 3-8 ng/mL. Previous doses of oral prednisone were continued and gradually tapered to a minimal maintenance dose (prednisone 10 mg/day) by 10-20% every one or two weeks. All previous immunosuppressants were withdrawn. Patients were observed over a period of six months after the initiation of tacrolimus therapy. Patients continued tacrolimus after six months and gradually decreased to a minimal dose after platelet count achieved complete response (CR).
Laboratory analyses
The clinical effect of tacrolimus treatment for patients was evaluated by analysis of platelet counts, at baseline and after one, three and six months of tacrolimus treatment. Levels of anti-double-stranded DNA (anti-dsDNA) antibodies and complement C3 and C4 were determined individually.
Response criteria
Response criteria were defined as follows. A complete response (CR) was defined as an increase in the platelet count greater than 100 Â 10 9 /mL and maintenance of a platelet count greater than 100 Â 10 9 /mL for at least four weeks. A partial response (PR) was defined as an increase in the platelet count to 50 Â 10 9 /mL to 100 Â 10 9 /mL or more than twice the platelet count before tacrolimus treatment that was maintained for at least four weeks. Treatment failure (no response [NR]) was defined as a platelet count less than twice that before tacrolimus treatment.
Tolerability
Safety and tolerability were evaluated based on the incidence of adverse effects (AEs) up to and including the safety follow-up visit.
Statistical analysis
Statistical analysis was carried out using the Statistical Package for the Social Sciences (version 19.0; SPSS, Inc., Chicago, IL, USA). Means with standard deviations (SD) and percentages were used to describe the clinical characteristics of patients. Nonparametric methods were used for statistical evaluation of data in most cases because of the small sample size and uneven distribution. Analysis of variance is conducted for comparison of different laboratory variables at baseline and during follow-up. A significance level of 0.05 was used.
Results
Demographic and baseline characteristics
The patients' main characteristics are summarized in Table 1 . There were 20 patients, 16 female patients and four male patients. Their mean age was 42.85 years (range, 25 to 57 years). The median disease duration before tacrolimus treatment was 2.68 years (range, 0.1 to 6.1 years).
Response of tacrolimus treatment
All patients had severe thrombocytopenia. A significant increase (CR or PR) in platelet count was observed in most patients, starting at one month after initial tacrolimus treatment (Figure 1(a) ). Three patients (15%) did not respond to tacrolimus treatment, three patients (15%) achieved CR, and the other 14 patients (75%) achieved PR. After three months of tacrolimus treatment, the platelet counts of all but one patient was significantly improved. PR was seen in 14 patients (75%), and the CR rate increased to 25% (five patients). After six months, all patients attained PR or CR without relapse and the rate of CR increased to 75% (Figure 1(b) , Table 2 ).
Clinical assessment of tacrolimus treatment
All patients had active disease. The disease activity was measured by the disability index (DAI). Compared to before treatment, the DAI score was markedly decreased in most patients after tacrolimus treatment (Figure 2(d) ). The levels of serum C3 and C4 were increased (Figure 2(a) and  (b) ). The levels of anti-dsDNA antibodies were slightly decreased (Figure 2(c) ). These changes all reached statistical difference compared to before treatment values (P < 0.05).
Adverse effects
In general, tacrolimus was well tolerated. Dyspepsia was the most frequently reported adverse event in three patients receiving tacrolimus (15%). Headache was reported in two patients (10%). Abnormal liver function occurred in two patients (10%). Allergy occurred in one patient (5%). Only one patient suffered minor infections but did not require hospital admission (Table 3) .
Discussion
Tacrolimus is a commonly used and effective drug in organ transplantation. As we know, thrombocytopenia and thrombotic thrombocytopenic purpura (TTP) are rare, but well described, complications in organ transplant patients receiving tacrolimus. Boctor reported a 56-year-old female with a history of lung transplant who presented to the hospital with thrombocytopenia while receiving tacrolimus for 36 months. 15 Arai et al. reported a 61-year-old woman with hepatitis C-related cirrhosis who underwent living donor liver Efficacy and safety of tacrolimus in SLE with thrombocytopenia Y Li and X Feng transplantation. After transplantation, severe thrombocytopenia (platelet count 17 000/mL) developed; suspecting tacrolimus as the inducer of this side effect, this was changed to CSA, after which the platelet count gradually recovered. 16 A study reported that, of 764 SOT patients, 19 (2.4%) developed immune cytopenias. Standard therapies for immune cytopenias were often used but ineffective. The most effective therapy for the immune cytopenia was changing immunosuppression from tacrolimus to another agent. 17 Thrombocytopenia is the most common hematologic complication of SLE. The mechanism of thrombocytopenia in lupus is complex. T cell (cellular immunity) mediated immune thrombocytopenia is one of the most important factors. Other factors may include antiplatelet antibody production, increasing peripheral damage, antiphospholipid antibodies. 18 Tacrolimus is a T cell-specific calcineurin inhibitor that prevents activation of T helper cells. It can potently inhibit T cell activation-induced TNF-a and interleukin (IL)-1b production in vitro by human peripheral blood mononuclear cells. 19 In addition, tacrolimus has been shown to inhibit IL-10 production. The ability of tacrolimus to affect T cells and IL-10 may be important in the immunotherapeutic strategy of SLE treatment. Tacrolimus can help to improve platelets in lupus, which has been observed in some clinical cases. In a retrospective analysis, 15 lupus patients presented with leukopenia and thrombocytopenia. Thirteen patients were treated with immunosuppressants, including CSA, tacrolimus, cyclophosphamide and mycophenolate mofetil. Complete remission was achieved in 14 patients. 20 The role of tacrolimus in the treatment of thrombocytopenia in patients with SLE has not been reported. We retrospectively analyzed the data for 20 SLE patients with refractory thrombocytopenia. Our results showed that the platelet count of all but one patient significantly improved and 19 of the 20 patients achieved CR or PR after tacrolimus treatment. The rate of CR reached 75% after six months of treatment. These results suggest that tacrolimus has a significant effect on the thrombocytopenia of SLE. After a month of tacrolimus therapy, three patients reached CR, 14 patients achieved PR, and only three patients did not significantly improve. These results show that the effect of tacrolimus is relatively rapid. The dosage of tacrolimus we used in this study was 2 mg per day, which is lower than that generally used for the treatment of lupus nephritis. It is possible that a higher dosage might result in greater therapeutic efficacy, but one would also expect more frequent adverse effects. In the process of small dose application, tacrolimus was well tolerated and side effects were usually minor. Individual patients had headache, diarrhea, or abnormal liver function. Moreover, these adverse reactions were relatively mild. Druginduced nephrotoxicity is a major concern with the long-term use of calcineurin inhibitors, but this did not occur in these 20 patients. 21 In addition to the analysis of the platelet count, we analyzed the lupus activity index. Complement consumption is a well-known SLE activity marker. Low baseline C3 levels seem to correlate with an increased risk of relapse in thrombocytopenia in patients with SLE and predict subsequent C3 measurements. Active patients with a history of thrombocytopenia and a low complement level are likely to experience relapse in thrombocytopenia, regardless of other system flares. 22 Compared with pretreatment, the levels of C4 and C3 were significantly higher in patients treated with tacrolimus. DAI was markedly decreased in most patients after tacrolimus treatment. Anti-dsDNA antibody levels were slightly decreased. These results suggest that tacrolimus can not only improve the platelet count, but also improve the body's activity indicators in patients with lupus.
However, this study has several limitations. First, it was not a randomized control trial. Second, the sample size was relatively small. Larger samples might produce a different result. Third, the period of observation was not long enough. The long-term effect of tacrolimus on thrombocytopenia needs to be studied further. Finally, there are the general limitations of observational and retrospective analysis. Although every effort was made to control for confounding differences among patients, unobserved confounding factors may have led to bias that was not fully adjustable.
In conclusion, our study found that a six-month course of tacrolimus is an effective treatment for SLE patients with refractory thrombocytopenia. However, the long-term effect and optimal regimen of tacrolimus require further study.
